Show
Sort by
-
- Journal Article
- A1
- open access
The prognostic value of IKZF1(plus) in B‐cell progenitor acute lymphoblastic leukemia : results from the EORTC 58951 trial
-
CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation : results of EORTC Children Leukemia Group study 58951
-
Pediatric randomized trial EORTC CLG 58951 : outcome for adolescent population with acute lymphoblastic leukemia
-
Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)
-
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials
-
- Journal Article
- A1
- open access
Prolonged versus standard native E-coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma : final results of the EORTC-CLG randomized phase III trial 58951
-
Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials
-
Impact of age and treatment group in childhood high hyperdiploid low risk B-cell acute lymphoblastic leukemia (ALL) : results of the CLG-EORTC 58951 study
-
Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics
-
Results of a feasibility and phase II study on bortezomib (BTZ) in pediatric multiply relapsed of refractory acute lymphoblastic leukemia: complete hematological responses with a modestly intensive regimen including BTZ